Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Richards

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Gut|December 21, 2018
Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver diseaseCyrielle Caussy, Veeral H Ajmera, Puneet Puri, et al.
Gastroenterology|December 3, 2016
Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver DiseaseCharlie C Park, Phirum Nguyen, Carolyn Hernandez, et al.
Nature Communications|March 31, 2019
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver diseaseCyrielle Caussy, Anupriya Tripathi, Greg Humphrey, et al.
Gastroenterology|April 17, 2018
Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseVeeral Ajmera, Charlie C Park, Cyrielle Caussy, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2023
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLDBeom K Kim, Nicole Bernstein, Daniel Q Huang, et al.
Hepatology (Baltimore, Md.)|April 24, 2019
MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)Veeral H Ajmera, Edward Cachay, Christian Ramers, et al.
Alimentary Pharmacology & Therapeutics|February 14, 2025
Clinical Trial to Assess the Safety and Tolerability of Anti-IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol-Associated Liver DiseaseLuis Antonio Diaz, Sheldon Morris, Shravan Dave, et al.
Hepatology (Baltimore, Md.)|March 13, 2019
Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance ElastographyCyrielle Caussy, Meera Bhargava, Ida F Villesen, et al.
Journal of Hepatology|August 16, 2022
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLDBeom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Cell Metabolism|July 2, 2020
A Universal Gut-Microbiome-Derived Signature Predicts CirrhosisTae Gyu Oh, Susy M Kim, Cyrielle Caussy, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Gut|December 21, 2018
Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver diseaseCyrielle Caussy, Veeral H Ajmera, Puneet Puri, et al.
Gastroenterology|December 3, 2016
Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver DiseaseCharlie C Park, Phirum Nguyen, Carolyn Hernandez, et al.
Nature Communications|March 31, 2019
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver diseaseCyrielle Caussy, Anupriya Tripathi, Greg Humphrey, et al.
Gastroenterology|April 17, 2018
Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseVeeral Ajmera, Charlie C Park, Cyrielle Caussy, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2023
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLDBeom K Kim, Nicole Bernstein, Daniel Q Huang, et al.
Hepatology (Baltimore, Md.)|April 24, 2019
MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial)Veeral H Ajmera, Edward Cachay, Christian Ramers, et al.
Alimentary Pharmacology & Therapeutics|February 14, 2025
Clinical Trial to Assess the Safety and Tolerability of Anti-IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol-Associated Liver DiseaseLuis Antonio Diaz, Sheldon Morris, Shravan Dave, et al.
Hepatology (Baltimore, Md.)|March 13, 2019
Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance ElastographyCyrielle Caussy, Meera Bhargava, Ida F Villesen, et al.
Journal of Hepatology|August 16, 2022
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLDBeom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Cell Metabolism|July 2, 2020
A Universal Gut-Microbiome-Derived Signature Predicts CirrhosisTae Gyu Oh, Susy M Kim, Cyrielle Caussy, et al.
Pageof 8